전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs
AntibodyCurated CoreFDAAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous B7-H3 CAR T (Autologous B7-H3 CAR T)

Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleBeijing Chest HospitalPhase 2

Surufatinib Durvalizumab EP/EC (Surufatinib Durvalizumab EP/EC)

Extensive-stage Small-cell Lung Cancer · Extensive-stage Small-cell Lung Cancer

#Extensive-stageSmall-cellLungCan#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Active